4.96
-2.36%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Shapuaisi Pharmaceutical Co
Its shares trade on Shanghai under the ticker 603168.SS. It has been listed since 2 July 2014. In the fiscal year to 31 December 2025, it reported revenue of CN¥462.8m and a net loss of CN¥238.7m. At that date it held total assets of CN¥1.87bn and shareholders' equity of CN¥1.35bn.
Zhejiang Shapuaisi Pharmaceutical Co., Ltd. engages in the manufacture and distribution of medicines and other pharmaceutical goods. The company is headquartered in Jiaxing, Zhejiang. The company went IPO on 2014-07-02. is a China-based company principally engaged in the production, research, development and sale of chemical medicine and Chinese patent drugs. The firm's chemical medicine products mainly include Shapuaisi Bendazac Lysine Eye Drops, infusion products and cefixime products. The firm's Chinese patent drugs include kidney tonifying and nerve soothing products, such as Sizi Tianjing Capsules and Compound Gaoshan Hongjingtian Solution. The firm distributes its products in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Jul 2014
- Employees
- 1,241
- Website
- zjspas.com ↗
Leadership
Pay as last reported
- Mr. Hongli LinChairman of the Board, General Manager, since 2024
- Mr. Xiusong LinChief Financial Officer, Deputy General Manager, Director, since 2020
- Mr. Hongsheng XuDeputy General Manager
- Mr. Mingxiong HuangSecretary of the Board, Director, Head of the General Manager’s Office, since 2022
- Mr. Kai LinDirector
- Mr. Weimin WangDirector
- Mr. Jianguo WuDirector
- Mr. Shengqun ChenIndependent Director
- Mr. Jiwei SunIndependent Director
- Mr. Shifu YanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Shapuaisi Pharmaceutical Co Ltd employs 1241 full-time staff members in China.
- The company manufactures Shapuaisi Bendazac Lysine Eye Drops for the domestic market.
- Zhejiang Shapuaisi Pharmaceutical Co Ltd produces cefixime products for local distribution.
Weaknesses
- The firm distributes its products exclusively in the domestic Chinese market.
- Zhejiang Shapuaisi Pharmaceutical Co Ltd lacks international market presence data.
- The company relies heavily on chemical medicine production lines.
Opportunities
- Sizi Tianjing Capsules offer potential growth in kidney tonifying segments.
- Compound Gaoshan Hongjingtian Solution could expand nerve soothing product lines.
- Infusion products may attract new domestic healthcare providers.
Threats
- Domestic market competition may reduce Shapuaisi Bendazac Lysine Eye Drops sales.
- Regulatory changes in China could impact chemical medicine production costs.
- Fluctuating demand for Chinese patent drugs affects revenue stability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.